LONDON & RESEARCH TRIANGLE PARK — ReViral, a clinical-stage biopharmaceutical company focused on novel antiviral treatments for diseases caused by the respiratory syncytial virus (RSV), has raised a whopping $44 million Series C financing led by CR-CP Life Science Fund.

Additional investors included Andera Partners, Brace Pharma Capital, Green Sands Equity, New Leaf Venture Partners, Novo Holdings, OrbiMed Advisors, and Perceptive Advisors.

Jason Zhou M.D., CEO and Managing Director of CR-CP Life Science Fund, joins the ReViral Board of Directors.

The company has dual headquarters — in Stevenage, UK and Durham, North Carolina.

“We are delighted by the strong financial support from this leading syndicate of healthcare investors, and we welcome Jason to our Board,” said its CEO Alex Sapir, in a statement.

RSV is a respiratory pathogen that can lead to severe and life-threatening lower respiratory tract infections (LRTIs) in high-risk populations, such as infants, immunocompromised patients, and the elderly.

The US-Based National Institute of Health (NIH) estimates that, globally, RSV affects approximately 64 million people and causes approximately 160,000 deaths each year.

In the United States, nearly all children become infected with RSV by age 2, with 75,000 to 125,000 of them hospitalized each year.

Currently, there are no effective therapeutic treatment options for patients who develop RSV infection.

Founded in 2011, ReViral’s lead product candidate, sisunatovir, is an orally administered fusion inhibitor currently being evaluated in two global Phase 2 clinical studies: one in a pediatric patient population and the other in an adult stem-cell transplant patient population.

In addition, the company has an N-protein replication inhibitor program in late preclinical development. Both programs were discovered in-house and the company has retained worldwide development and commercialization rights.

Sapir said the proceeds from the fundraise will be used to support Phase 2 clinical development for sisunatovir, and to progress our N-protein replication inhibitor program into Phase 1.